BLCO Stock Overview
Bausch + Lomb Corporation operates as an eye health company worldwide.
No risks detected for BLCO from our risk checks.
Bausch + Lomb Corporation Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$15.25|
|52 Week High||US$20.20|
|52 Week Low||US$12.20|
|1 Month Change||7.55%|
|3 Month Change||-11.18%|
|1 Year Change||n/a|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-23.75%|
Recent News & Updates
Bausch + Lomb: A Solid Play In Challenging Economic TimesNov 09
Bausch + Lomb reports Q3 mixed earnings; narrows FY22 guidance rangeNov 02
|BLCO||US Medical Equipment||US Market|
Return vs Industry: Insufficient data to determine how BLCO performed against the US Medical Equipment industry.
Return vs Market: Insufficient data to determine how BLCO performed against the US Market.
|BLCO Average Weekly Movement||6.5%|
|Medical Equipment Industry Average Movement||8.9%|
|Market Average Movement||7.4%|
|10% most volatile stocks in US Market||15.5%|
|10% least volatile stocks in US Market||3.3%|
Stable Share Price: BLCO is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 6% a week.
Volatility Over Time: BLCO's weekly volatility (6%) has been stable over the past year.
About the Company
Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions comprising eye allergies, conjunctivitis, and dry eye.
Bausch + Lomb Corporation Fundamentals Summary
|BLCO fundamental statistics|
Is BLCO overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|BLCO income statement (TTM)|
|Cost of Revenue||US$1.50b|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||0.17|
|Net Profit Margin||1.54%|
How did BLCO perform over the long term?See historical performance and comparison